Join our daily newsletter At The Bell to receive exclusive market insights
- Oncology company Prescient Therapeutics (PTX) focused on advancing its targeted and cell therapies during the June quarter
- Promising trial data led the company to expand its PTX-100 therapy to treat T-cell lymphomas with recruitment expected to be completed by the end of 2022
- Importantly, a fourth patient with acute myeloid leukemia reported complete remission in a phase 1b study of PTX-200 combined with chemo
- Further, PTX unveiled its new clinic-ready CellPryme-M platform for enhancing cell therapies developed with Peter MacCallum Cancer Centre Melbourne
- Company shares are trading steady at 18 cents at 2:12 pm AEST
Prescient Therapeutics (PTX) advanced multiple clinical programs for its targeted and cell therapy drugs over the June quarter.
Following “excellent” safety data and encouraging early evidence of clinical efficacy, PTX expanded the phase 1B trial of its PTX-100 targeted therapy to treat T-cell lymphomas (TCL) which is a group of aggressive and rare blood cancers.
The oncology company expects to complete recruitment of 12 patients suffering relapsed and refractory TCL by the end of the year.
Additionally, a phase 1b study of PTX-200 combined with chemotherapy in people with acute myeloid leukemia (AML) reported that another patient in the study has had complete remission of their disease at the 45mg/m2 dose. This takes the total number of patients in the study reporting complete remission of their disease to four.
Importantly, Prescient developed the CellPryme-M platform with the Peter MacCallum Cancer Centre Melbourne.
The clinic-ready platform reportedly complements Prescient’s OmnICAR platform by solving some of the key problems that current and emerging cell therapies face.
CellPryme-M enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype which improves persistence and increases the ability to find and target tumours. The platform produces more favourable cell phenotypes that are known to drive “superior” clinical outcomes.
CellPryme-M is ready for clinical testing and presents commercial opportunities for the company to incorporate it into third party manufacturing processes.
In terms of its financial position, the company reported net operating outflows of $1.2 million, with around $500,000 invested in research and development activities in Australia and the US.
Prescient ended the quarter with $12.3 million in cash.
PTX was trading steady at 18 cents at 2:12 pm AEST.
